Changing the Face of eTMF with new Technologies

Barry Sacks, Chief Technology Officer

Bring Order, Stability, and Control to Your TMF



TMF TECHNOLOGY

TMF PROCESSING

TMF EXPERT SERVICES

Bring Order, Stability, and Control to your Trial Master File





Helping you stay in the TMF Healthzone





The right Technology is crucial to maintaining TMF Health New tools such as AI, ML, ANN, NLP will change the game



Today's Presenter



Barry Sacks Chief Technology Officer

Barry Sacks is the Chief Technology Officer at Phlexglobal. Barry was previously a Partner within Digital Works Group's Product, Project and Technology team bringing over 25 years of experience leading a variety of start-up, SME and blue-chip organizations through the design, delivery, management and growth of innovative digital products and services. An accomplished technology entrepreneur, corporate director and consultant having worked throughout the UK, Europe, Australia and the US. Prior to Digital Works Group, Barry founded a SaaS venture, was the Global CTO for the FinTech MyJar, the CTO (Corporate Venturing) for Diageo, as well as enjoying a varied interim career.



Changing the Face of eTMF with new Technologies

Barry Sacks

Chief Technology Officer





Who is using Artificial Intelligence (AI) today?

Al is already ubiquitous, we are all using it every single day





But there is a lot of Hype surrounding Al

"Robots will take our jobs. We'd better plan now, before it is too late"



Al implementation is finally coming of age But there is still a myth of complexity that creates barriers for adoption

"Everyone talks about it, nobody really knows how to do it, everyone thinks everyone else is doing it, so everyone claims they are doing it."

Dan Ariely - James B. Duke Professor of Psychology and Behavioral Economics at Duke University



"Gradually then Suddenly" – the evolution of AI How fast is AI accuracy improving? In fact very fast...

What have these faces got in common?



"Disruptive trends in an industry can rapidly accelerate -Marcelo Ballve leaving the unprepared in the dust"



The many fields of Al

Artificial Intelligence contains many subfields, those of interest to us are:

Machine Learning (ML) **Artificial Neural Networks (ANN)** Natural Language Processing (NLP) **Deep Learning Big Data**



ML is the inverse of programming With ML, computers write their own programs so we don't have to

Traditional software programming:

each algorithm has an input and an output, data goes into the computer, the algorithm executes, and out comes the result.

Machine Learning turns this around:

- in goes the data and the desired result and out comes the algorithm that turns one into the other.
- **Learning algorithms** are algorithms that make other algorithms.



Artificial Neural Networks (ANN) ANNs learn without being programmed with any task-specific rules





Input layer

Hidden layer 1

... Hidden layer k

. . .

Output layer

ANNs with more than one layer are Deep Learning networks Different layers can perform different kinds of transformations



Natural Language Processing

Ability for machines to understand and interpret human language

Natural Language Processing is often compared with text analytics

Text analytics counts, groups and categorizes words to extract structure and meaning from large volumes of textual content

Natural Language Processing is used to understand the meaning (semantics) and structure of given text data

NLP and text analytics can be used together to extract meaningful information from structured and unstructured content



Deep Learning Working with text in eTMF unstructured documents

Linguistic methods for natural language processing required experts in language defining rules to cover specific cases

Statistical methods improve upon classical linguistic methods by learning rules and models from data

Deep learning methods out-compete the statistical methods on challenging unstructured natural language processing problems

With NLP and Deep Learning text extraction and eTMF content classification is now possible through automation



Big Data and Machine Learning Large volumes of data are required to train and improve ML accuracy

Training Machine Learning algorithms within Artificial Neural Networks using Natural Language Processing and Deep Learning to classify unstructured content requires lots of **Big Data**

With no data there is nothing from which the machine can learn With Big Data (large volumes of data) there is lots to learn from

A typical TMF of 2m documents may contain **700 different sub artifacts** Of these only 3 would individually make up more than **5% of the TMF**



ML now combines nearly all subfields of Al

The term ML is now used interchangeably for computational AI application







ML in Clinical Trials

Learning algorithms are used extensively in trials (e.g. to determine):

Where genes are located in a DNA molecule Where superfluous bits of RNA get spliced out How proteins fold into their characteristic shapes How different conditions affect the expression of different genes How to weed out molecules likely to have nasty side effects Whether drugs they will work so only the most promising get tested To avoid expensive failures after human trials have begun



Using Al in an eTMF How Al technologies are being used in an eTMF today

Using AI to assess TMF content provided by Sponsors and CROs against DIA reference models or Sponsor originated mappings Scoring completeness, quality and compliance in heatmaps **Enhancing process automation within TMF user workflows** Al assisted document classification, indexing and filing Improving TMF quality using machine extracted meta-data and automated content classification (with or without user interaction)



eTMF NLP document Auto-classification Auto classifying documents within Artifacts and Sub-artifacts

10,000 unclassified documents Manual processing ~21 days **Autoclassification** reduced effort by 70% Study processed in ~6.5 days



PHLEXGLOBAL

eTMF NLP document Auto-indexing Automated data indexing via data mining of multiple document types

10,000 unclassified documents

Manual indexing & QC ~4 mins per document

Autoclassification and text extraction reduced overall effort by 50%

Average document QCd in ~2 mins



Protocol number extracted from SVR ~80% accuracy Physicians name extracted from CV (first & last name) ~70% accuracy



Al will impact current eTMF processes

Increased confidence (and accepted regulation) will allow full automation



Artifacts with **high confidence** once proven can be fully **AI indexed** Artifacts with **medium confidence** can be AI indexed with **human QC** Artifacts with **low confidence** can be indexed manually with **AI Assistance**



Al will move low-value manual input effort to high-value QC effort

PhlexEview Dashboard Documents eTransmittal Queries Search Approval Reports Study Mgmt		🖙 📸 🔧 ? Mark Flint 💶		
S357_TestProtocol1_05.02.04 Principal Investigator Curriculum Vitae_Principal Investigator Curriculum Vitae RINAL & QCD				
INVESTIGATOR ONE PAGE CV	>	22-May-2007	97% 🗸	
Full Name: Lille Mark J Date: 22-May-20 Last Name First Name Middle Initial dd/mmn Study Site Affiliation: (e.g., Principal Investigator, Sub Investigator, Coordinator) Middle Initial dd/mmn © Principal Investigator Sub Investigator Coordinator Professional Mailing Address: (Include institution name.) Study Site Address: (Include institution name.) Study Site Address: (Include institution name.)	У7 УУУУУ 	01-Aug-1978	9%	
Barclay Hospital 82 Chalfont Road London NW8 5BH Barclay Hospital 82 Chalfont Road London NW8 5BH NW8 5BH	-	Version Filenote * N ~		
Telephone: 020 8775 6986 Telephone: 020 8775 6986 Academic Qualifications (most current date first) Institution, Country Degree/Certification Date (mmm/yyyy) Institution, Country MD July 1981 Portsmouth University, Portsmouth BSc Aug 1978 Portsmouth University, Portsmouth BA June 1971 Williams Comprehensive, Bournemouth		Subject Number Case Number Approval * (No Data) ~ Signature * (No Data) ~		
Current and Previous 4 Relevant Positions Including Academic Appointments (most current date first): Dates In Years Title Institution/Company, Country 1996 - Current Doctor Barclay Hospital, London 1994 - 1996 Sub Investigator Knight Pharmaceuticals, Portsmouth 1992-1994 Monitor Knight Pharmaceuticals, Portsmouth Brief Summary of Relevant Clinical Research Experience: During my carcer in clinical research. I have gained experience in most aspects of the clinical trial process	•	Mark J Lille	94% 🗸	
License/ID Number: 594647899VX72GB Licensed in State/Province/Country: London G Signature: Signature Date:		Lille J Mark	42%	
(Signaluse fequired for ALL Investigators) NOTE: CV MUST BE LIMITED TO <u>ONE PAGE</u> FOR INCLUSION IN THE ICH-E3 COMPLIANT CLINICAL ST REPORT. PLEASE NO ATTACHMENTS, AND NO TEXT ON THE REVERSE SIDE.	UDY	Mark Lille	16%	
Showing Result 6 of 87 < >				

PHLEXGLOBAL

The future for AI based technologies in eTMF Opportunities exist to further extend the use of AI technologies in eTMF

- Moving from retrospective reporting to predictive analytics
- Simplifying distributed/mobile submission processes through automated filing
- Using the "power of the crowd" to predict TMF quality issues before they occur
- Using AI confidence scores to direct skilled resources to known risk areas
- Higher value resource contributions to assessing eTMF quality and accuracy, compliance and risk
- Integration of other emerging technologies e.g. Blockchain to validate content chain of custody across the entire clinical trial lifecycle (not just within eTMF)



A (near) future vision for eTMF Al will change the focus of roles supporting and managing the eTMF

BU		Analytics Study Inspection Management Readiness	
	bsite	Quality Review	
H F	API, We	Processing	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Η	bile App	Study Setup Placeholders Heatmaps Workflow	Gipicial → Safety → Concernent of the second secon
VIT	δ Σ	Metadata Documents	Sites / ISF ←→
AC		PhlexEview Repository Veeva D2	$ \begin{array}{c} & \longleftrightarrow & Safety \\ & \leftarrow & Reg & \leftarrow & Z \end{array} $

